Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage:a nationwide, population-based study in the Netherlands, 1989–2018
It is unclear whether survival in diffuse large B-cell lymphoma (DLBCL) continues to increase in an era where rituximab-containing chemotherapy reigns for almost two decades. Therefore, we evaluated trends in primary therapy and relative survival (RS) among Dutch DLBCL patients diagnosed between 1989 and 2018. Analyses were performed separately according to the stage I (N = 6952) and stage II–IV disease (N = 20,676), stratified by calendar period and age (18–64, 65–74, and ≥75 years). The use of chemotherapy ± radiotherapy increased over time across all age and stage groups. As of the mid-2000... Mehr ...
Verfasser: |
Durmaz, Müjde
Visser, Otto
Posthuma, Eduardus F.M.
Brouwer, Rolf E.
Issa, Djamila E.
de Jong, Daphne
Lam, King H.
Blijlevens, Nicole M.A.
Zijlstra, Josée M.
Chamuleau, Martine E.D.
Lugtenburg, Pieternella J.
Kersten, Marie José
Dinmohamed, Avinash G. |
Dokumenttyp: |
Artikel |
Erscheinungsdatum: |
2022 |
Reihe/Periodikum: |
Durmaz , M , Visser , O , Posthuma , E F M , Brouwer , R E , Issa , D E , de Jong , D , Lam , K H , Blijlevens , N M A , Zijlstra , J M , Chamuleau , M E D , Lugtenburg , P J , Kersten , M J & Dinmohamed , A G 2022 , ' Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage : a nationwide, population-based study in the Netherlands, 1989–2018 ' , Blood Cancer Journal , vol. 12 , no. 3 , 38 . https://doi.org/10.1038/s41408-022-00637-1 |
Sprache: |
Englisch |
Permalink: |
https://search.fid-benelux.de/Record/base-26840991 |
Datenquelle: |
BASE;
Originalkatalog |
Powered By: |
BASE |
Link(s) :
|
https://pure.eur.nl/en/publications/e26f4f1b-1f17-4526-a766-c5db0bb27a3a |